Top in hem/onc: Cancer Moonshot progress, screening in underserved areas
Since 2016, the National Cancer Institute said it has invested more than $1 billion in the Cancer Moonshot program, which has contributed to over 240 projects across more than 70 research initiatives.
A look at the work accomplished through the program and what remains to be done was the top story in hematology/oncology this week.
Another top story discussed the See, Test & Treat Program, which provides same-day cancer screening and health education services to women in underserved communities, many of whom would not otherwise be able to access services for socioeconomic reasons.
Read these and more top stories in hematology/oncology below:
Cancer Moonshot has ‘galvanized’ research community, NCI director says
Inspired by the death of then-Vice President Joe Biden’s son, Beau, due to glioblastoma, the NCI launched the Cancer Moonshot in 2016 with the goal of advancing cancer research and treatment. Read more.
‘I’ve never been treated so well’: Same-day cancer screening program helps reduce barriers
While on-site at a same-day cancer screening program he helped to implement, Timothy Craig Allen, MD, JD, FCAP, came across a crying woman. Read more.
Cisplatin-induced hearing loss common among very young children early in treatment
Young children with cancer who received cisplatin chemotherapy had a higher incidence of cisplatin-induced hearing loss than older children, according to study results published in Cancer. Read more.
Lung cancer trial enrollment dropped 43% amid COVID-19 pandemic
Enrollment in lung cancer clinical trials declined by more than 40% amid the COVID-19 pandemic, according to results of a global survey presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer. Read more.
Researchers use ‘humanized’ CAR T cells to improve treatment durability for patients with ALL
The FDA approved the first chimeric antigen receptor therapy in 2017, authorizing tisagenlecleucel for treatment of children or young adults with relapsed or refractory B-cell acute lymphoblastic leukemia. Read more.